DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Any other approved Antiepileptic Drug; CANNABIDIOL; CBD; CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.; CLOBAZAM; Cannabidiol; Cannabidiol (CBD); Cannabidiol Oral Solution; Carisbamate; Clobazam; Clobazam High Dose; Clobazam Low Dose; Clobazam Medium Dose; Clobazam PhEur; Clobazam Pheur; Clobazam Tablets; Clobazam Tablets 10mg; Clobazam Tablets 20mg; Clobazam Tablets 5mg; E2007; E2080; EZOGABINE (US ONLY); EZOGABINE (US only); Ezogabine; Ezogabine/retigabine; FENFLURAMINE HYDROCHLORIDE; Fenfluramine; Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine; Fenfluramine hydrochloride (colorless); Fycompa; GW582892; GWP42003-P; GWP42003-P 20 mg/kg/day Dose; Inovelon; Investigators Choice of Approved AED; Investigators choice of approved AEDs; Lamictal; Lamotrigine; Melatonin; PERAMPANEL; Perampanel; Placebo; Potiga; Procedure: 12-Lead ECG; RETIGABINE; RETIGABINE/EZOGABINE; RUFINAMIDE; Retigabine; Retigabine/Ezogabine; Retigabine/ezogabine; Rufinamide; Rufinamide (E2080); Rufinamide oral suspension; Sodio valproato; TAK-935; Topimarate; Topimarato; Topiramate; Turmeric; ZX008; ZX008 (Fenfluramine Hydrochloride); ZX008 0.2 and 0.8 mg/kg/day; ZX008 0.2 or 0.8 mg/kg/day

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-023505-36-IT (EUCTR)	29/09/2011	05/01/2012	A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome	A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome - E2080-G000-303	Lennox Gastaut Syndrome MedDRA version: 14.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Inovelon Other descriptive name: Rufinamide oral suspension INN or Proposed INN: lamotrigine Other descriptive name: Lamictal INN or Proposed INN: sodio valproato INN or Proposed INN: topimarato Other descriptive name: topimarate	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	75		Greece;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2010-023505-36-IT
(EUCTR)

29/09/2011

05/01/2012

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Inovelon
Other descriptive name: Rufinamide oral suspension
INN or Proposed INN: lamotrigine
Other descriptive name: Lamictal
INN or Proposed INN: sodio valproato
INN or Proposed INN: topimarato
Other descriptive name: topimarate

EISAI LTD UK

NULL

Not Recruiting

Female: yes
Male: yes

Greece;Italy